Shareholding disclosure

Idorsia Pharmaceuticals Ltd

Declared position

15.32%

Threshold

Crossed upwards

Timeline

Published

27.11.2018

Transaction

20.11.2018

Voting rights breakdown

Voting rights acquired15.32%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAIBN00017

Beneficial owner

Idorsia Pharmaceuticals Ltd

Declared address

Idorsia Pharmaceuticals Ltd, 4123 Allschwil

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Idorsia Pharmaceuticals Ltd

Santhera Pharmaceuticals Holding AG27.11.2018TAIBN00017

Disclosure summary

Idorsia Pharmaceuticals Ltd disclosed a holding in Santhera Pharmaceuticals Holding AG on the acquisition side, published by SIX Exchange Regulation on 27.11.2018, at 15.32% of voting rights. Notice category: Single shareholder.

Disclosed position

15.32%

Voting rights acquired

Voting rights acquired15.32%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Idorsia Pharmaceuticals Ltd disclosed a holding in Santhera Pharmaceuticals Holding AG, published on 27.11.2018.

Publication date27.11.2018

Transaction date20.11.2018

Issuing companySanthera Pharmaceuticals Holding AG

Beneficial ownerIdorsia Pharmaceuticals Ltd

Declared addressIdorsia Pharmaceuticals Ltd, 4123 Allschwil

CategorySingle shareholder

Voting rights acquired15.32%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDTAIBN00017

Commercial register

CHE-232.876.339

Registered

Zefix record

Source: SIX Exchange Regulation · Publication date: 27.11.2018

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open